Efficacy and Safety of AM-101 in the Treatment of Acute Peripheral Tinnitus 3
Latest Information Update: 25 Aug 2022
At a glance
- Drugs Esketamine (Primary)
- Indications Tinnitus
- Focus Registrational; Therapeutic Use
- Acronyms TACTT3
- Sponsors Altamira Therapeutics; Auris Medical
- 13 Mar 2018 Primary endpoint [Efficacy endpoint - alternate primary efficacy endpoints: Tinnitus Functional Index (TFI)] has not been met.
- 13 Mar 2018 According to an Auris Medical media release, the Company is investigating the outcomes and will provide an update in due course.
- 12 Jan 2018 Status changed from active, no longer recruiting to completed.